Lovenox outsells Arixtra in the US market by 10:1, and hence the availability of a generic version of Arixtra should have little if any measurable impact on Lovenox.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.